Moving beyond parity: Ensure clinical accountability in behavioral health care

That message stems from the Mental Health Parity and Addiction Equity Act (MHPAEA), a law intended to ensure mental health and substance use disorder benefits are not treated more restrictively than medical benefits.

The intent of MHPAEA is sound. The way it has been operationalized across employer-sponsored health plans is where risk begins.

The real problem: Abdication, not parity

For decades, employers largely stepped away from health care decision-making, delegating clinical and financial oversight to carriers, brokers, PBMs, and behavioral health carve-outs.

Many of those entities are compensated on volume, spread pricing, or carrier relationships rather than outcomes, which can create misaligned incentives.

Parity did not create this environment. Parity exposed it.

SUD treatment: Extreme variation, minimal accountability

Substance use disorder treatment is one of the most uneven areas of health care today.

Programs vary widely in clinical models, staff credentials, use of evidence-based practices, lengths of stay, and long-term outcomes.

Two programs can both be covered and parity compliant while producing dramatically different results and costs. Employers often fund that variation without visibility or control.

Recovery is real, but so are relapse risks

Receiving treatment and achieving long-term recovery are not the same outcome.

Decades of research demonstrate that substance use disorder behaves like other chronic medical conditions. Early relapse rates after treatment range from approximately 40% to 60%, similar to conditions such as hypertension or asthma. However, relapse risk declines substantially with sustained recovery over time.

Federal research and national reports confirm that long-term recovery is achievable and durable, particularly when individuals receive evidence-based care and appropriate ongoing support. Many adults who previously experienced substance use problems report that they now consider themselves in recovery.

These findings highlight the importance of treatment quality, appropriate levels of care, and continuity, not just initial access.

Cost is not a proxy for quality

Higher provider or treatment costs do not reliably deliver better outcomes.

Pricing is often influenced by marketing and amenities, geographic location, investor-backed growth models, and length-of-stay incentives rather than clinical effectiveness.

When treatment fails, costs compound through repeat admissions, pharmacy spend, disability leave, workplace safety risks, and lost productivity.

Parity can support access. It does not ensure effectiveness.

A hidden risk: Fragmented precertification

One of the least discussed but most consequential risks in behavioral health management is fragmented clinical oversight.

In many employer-sponsored health plans, one vendor manages medical precertification while another manages behavioral health or substance use disorder precertification. Each applies different clinical criteria and decision standards.

This fragmentation increases inconsistent care decisions, gaps in accountability, parity exposure, and legal and financial risk for employers.

When no single clinical authority owns the full picture, quality and compliance suffer.

Parity enforcement is no longer theoretical

Federal agencies are now treating Non-Quantitative Treatment Limitation compliance as operationally enforceable, not theoretical.

Recent reports from the U.S. Department of Labor confirm increased investigations, required corrective actions, and focused scrutiny on clinical standards, network adequacy, prior authorization practices, and utilization management processes that disproportionately impact mental health and substance use disorder benefits compared to medical and surgical services.

Employers should expect comparative analyses, documentation requests, audits, and corrective action requirements when parity inconsistencies are identified.

What to look for in a medical management vendor

Rather than focusing on specific products or services, employers should evaluate medical management partners against objective standards that support quality, consistency, and defensibility.

Key criteria include:

• Consistent application of evidence-based clinical criteria across medical, behavioral health, and substance use disorder care
• Defensible utilization management practices with documented parity and Non-Quantitative Treatment Limitation alignment
• Unified clinical oversight to reduce fragmentation and conflicting care decisions
• Navigation support that helps individuals access appropriate levels of care, not just available care
• Documentation and governance structures that withstand regulatory review and audit scrutiny

These standards distinguish vendors that bring clinical discipline and accountability from those that rely primarily on administrative processing or volume-based management.

Call to action

Employers facing rising behavioral health costs, increasing regulatory scrutiny, and uneven treatment outcomes should use this moment to reassess how substance use disorder care is managed within their health plans.

The most important questions extend beyond whether benefits are covered. They include how care decisions are made, how quality is measured, and whether management practices are consistent, defensible, and aligned with modern parity enforcement expectations.